title: [Quality of treatment after myocardial infarction: impact of hospital guidelines].
abstract: After myocardial infarction (MI), international societies of cardiology recommend an optimal treatment associating four classes of drugs, known as BASI combination (beta-blocker, antiplatelets, statin and inhibitor of the angiotensin converting enzyme). This study shows that the implementation of locally adapted guidelines in a regional hospital (CHCVs, Sion) significantly improve the treatment quality after MI, with a 10% increase of the BASI combination at discharge. Detailed results are discussed. Finally, we provide a table summarizing the optimal treatment strategy with drug examples including doses, which will be helpful to both general practitioners and specialists.
authors.affiliation: Service de Pharmacie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion. vera.vongunten@hospitalvs.ch
authors.forename: Vera
authors.initials: V
authors.lastname: von Gunten
authors.affiliation: Service de Cardiologie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion.
authors.forename: Christophe
authors.initials: C
authors.lastname: Sierro
authors.affiliation: Pharmacie des Hôpitaux de l'Est lémanique, Hôpital Riviera, site du Samaritain, Vevey.
authors.forename: Séverine
authors.initials: S
authors.lastname: Rosiak
authors.affiliation: Pharmacie des Hôpitaux de l'Est lémanique, Hôpital Riviera, site du Samaritain, Vevey.
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Weibel
authors.affiliation: Service de Médecine Interne du Centre hospitalier du Valais romand, Hôpital du Valais, Sion.
authors.forename: Pierre-August
authors.initials: PA
authors.lastname: Petignat
authors.affiliation: Service de Cardiologie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion.
authors.forename: Grégoire
authors.initials: G
authors.lastname: Girod
authors.affiliation: Service de Pharmacie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion.
authors.forename: Johnny
authors.initials: J
authors.lastname: Beney
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006761:Hospitals / Q000592:standards; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011787:Quality of Health Care; D012189:Retrospective Studies; D012955:Societies, Medical
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors